Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
GSK meningococcal vaccine accepted by US FDA for review
(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA). The FTSE 100 pharmaceuticals giant said the Prescription Drug User Fee Act (PDUFA) action date for the FDA's regulatory decision on the application was set for 14 February 2025.
It said the vaccine candidate, which it developed, offered broad coverage against the five most common groups of bacteria causing invasive meningococcal disease (IMD).
If approved, the vaccine could potentially streamline immunisation protocols by reducing the number of injections required.
The company said the innovative vaccine combines the antigenic components of two established meningococcal vaccines - Bexsero and Menveo - both known for their efficacy and safety profiles.
It said the MenABCWY combination targeted neisseria meningitidis bacteria groups A, B, C, W, and Y, which collectively account for a majority of IMD cases worldwide.
Simplifying immunisation through fewer shots aimed to enhance series completion and vaccination coverage, ultimately reducing the overall burden of IMD.
GSK said adolescents particularly stood to benefit as they were at higher risk of IMD and potential outbreaks.
The company described IMD as a severe and unpredictable illness with potentially life-threatening complications.
Despite treatment, the mortality rate remained significant, while survivors could face long-term consequences such as brain damage and hearing loss.
In the US, where meningococcal vaccine recommendations had covered all five serogroups since 2015, immunisation rates for IMD remained low, partly due to a complex vaccination schedule.
MenB, the most common group of IMD-causing bacteria in US adolescents and young adults, remained a significant concern.
Results from the phase three trial of the MenABCWY vaccine candidate showed promising outcomes, meeting all primary endpoints.
That included immunological non-inferiority to GSK's Meningococcal Groups A,C,Y, and W Vaccine and non-inferior immune responses against a broad range of MenB invasive strains.
The vaccine also demonstrated a favourable safety profile, consistent with both constituent vaccines.
At 0920 BST, shares in GSK were down 1.98% at 1,611p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.